The characteristics of BCR-CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccinated volunteers.

Publication date: Mar 01, 2024

The global COVID-19 pandemic has caused more than 1 billion infections, and numerous SARS-CoV-2 vaccines developed rapidly have been administered over 10 billion doses. The world is continuously concerned about the cytokine storms induced by the interaction between SARS-CoV-2 and host, long COVID, breakthrough infections postvaccination, and the impact of SARS-CoV-2 variants. BCR-CDR3 repertoire serves as a molecular target for monitoring the antiviral response “trace” of B cells, evaluating the effects, mechanisms, and memory abilities of individual responses to B cells, and has been successfully applied in analyzing the infection mechanisms, vaccine improvement, and neutralizing antibodies preparation of influenza virus, HIV, MERS, and Ebola virus. Based on research on BCR-CDR3 repertoire of COVID-19 patients and volunteers who received different SARS-CoV-2 vaccines in multiple laboratories worldwide, we focus on analyzing the characteristics and changes of BCR-CDR3 repertoire, such as diversity, clonality, V&J genes usage and pairing, SHM, CSR, shared CDR3 clones, as well as the summary on BCR sequences targeting virus-specific epitopes in the preparation and application research of SARS-CoV-2 potential therapeutic monoclonal antibodies. This review provides comparative data and new research schemes for studying the possible mechanisms of differences in B cell response between SARS-CoV-2 infection or vaccination, and supplies a foundation for improving vaccines after SARS-CoV-2 mutations and potential antibody therapy for infected individuals.

Concepts Keywords
Billion Antibodies, Neutralizing
Host Antibodies, Neutralizing
Storms Antibodies, Viral
Therapy Antibodies, Viral
Vaccines BCR-CDR3 repertoire
COVID-19 Vaccines
COVID-19 Vaccines
high-throughput sequencing
Post-Acute COVID-19 Syndrome
SARS-CoV-2 vaccine
single-cell sequencing


Type Source Name
disease MESH COVID-19
disease VO vaccinated
disease MESH infections
disease MESH cytokine storms
disease IDO host
disease MESH long COVID
disease MESH breakthrough infections
disease IDO infection
disease VO vaccine
disease MESH influenza
drug DRUGBANK S-Arsonocysteine
disease IDO cell
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination

Original Article

(Visited 1 times, 1 visits today)